The FDA Approves New Drug for a Skin Condition That Affects 32 Million Americans

This week the U.S. Food and Drug Administration (FDA) approved Eucrisa (crisaborole) ointment to treat mild to moderate eczema (atopic dermatitis) in patients two years of age and older.

You May Also Like: 7 Common Skin Care Conditions and Solutions

More commonly referred to as eczema, atopic dermatitis is a chronic inflammatory skin disease. The National Eczema Association reports that a substantial number of the U.S. population has symptoms of eczema—31.6 million people have eczema, and at least 17.8 million have moderate to severe eczema or atopic dermatitis.

"Today’s approval provides another treatment option for patients dealing with mild to moderate atopic dermatitis," said Amy Egan, deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research.

The new ointment is intended to be applied topically twice daily. The most common side effect of Eucrisa is application site pain, including burning or stinging.